These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21084040)

  • 1. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.
    Ma JD; Nguyen ET; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Lee LS
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):847-53. PubMed ID: 21084040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.
    Nguyen AN; Hoffman JT; Tsunoda SM; Jang IJ; Ma JD
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):468-75. PubMed ID: 22541751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
    Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
    Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.
    Masters JC; Harano DM; Greenberg HE; Tsunoda SM; Jang IJ; Ma JD
    Ther Drug Monit; 2015 Feb; 37(1):84-9. PubMed ID: 25004135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
    Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.
    Mueller SC; Drewelow B
    Eur J Clin Pharmacol; 2013 May; 69(5):1127-34. PubMed ID: 23131857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
    Lee LS; Bertino JS; Nafziger AN
    J Clin Pharmacol; 2006 Feb; 46(2):229-34. PubMed ID: 16432275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
    Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
    Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
    Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate.
    van Dyk M; Kapetas AJ; Hopkins AM; Rodrigues AD; Vourvahis M; Sorich MJ; Rowland A
    Front Pharmacol; 2019; 10():1120. PubMed ID: 31611799
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
    Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
    Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
    Chung E; Nafziger AN; Kazierad DJ; Bertino JS
    Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
    Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
    Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
    Greenblatt DJ; Peters DE; Oleson LE; Harmatz JS; MacNab MW; Berkowitz N; Zinny MA; Court MH
    Br J Clin Pharmacol; 2009 Dec; 68(6):920-7. PubMed ID: 20002087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.
    Penzak SR; Busse KH; Robertson SM; Formentini E; Alfaro RM; Davey RT
    J Clin Pharmacol; 2008 Jun; 48(6):671-80. PubMed ID: 18420532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.